Shanghai Pharma has been granted the exclusive rights of the new generation of lysovirus therapy for Yino Micropharmaceuticals in Greater China.

On August 6th, Ino Micropharma and Shanghai Pharmaceuticals jointly announced the signing of a licensing agreement under which Shanghai Pharma received exclusive clinical development and commercialization rights for the former lysovirus MVR-T3011 (T3011, intra-tumor injection) in Greater China (Chinese mainland, Hong Kong, Macau and Taiwan).
also retains the development and commercialization interest in MVR-T3011 outside Greater China.
the agreement, Shanghai Pharma intends to invest no more than 1.15 billion yuan, of which 850 million yuan will be invested in research and development milestones and 300 million yuan in sales milestones.
addition, the company will pay up to 12% of the annual net sales in Greater China based on the annual net sales of the MVR-T3011.
, was founded in 2015, the company's chairman and chief executive officer is Zhou Guoxuan academician.
company is committed to the development of a new generation of lysolytic tumor virus, while improving the ability of virus replication, to further improve the activity of viral lysolytic tumor, promote immune response.
Following the completion of the RMB102 million round of financing in January 2019, in June this year, Ino Micropharma announced the completion of a $58 million round B round of financing, led by Huagai Capital, Almond Capital, TongTron Weiye and Investment.
T3011 is a new generation of recombinant herpes lysomavirus developed by Ino Micropharma, which can be injected directly into the tumor and can be used to treat anti-tumor drugs for local late-stage, relapsed or metastasis solid tumors.
, according to the press release, T3011 uses the proprietary viral skeleton of Innod micropharmaceuticals, taking into account safety while improving the virus's replication and tumor resistance.
the cytokine combination IL-12 and Anti-PD-1 antibodies inserted by T3011 have novelty and clinical rationality, which can further enhance the immune synergetic anti-tumor effect.
successfully passed the clinical trial phase, it is expected to be another heavyweight treatment in the field of lysovirus drugs, after Amgen's T-VEC in the United States.
, T3001 has opened clinical trials in three countries: China, the United States and Australia.
July 2019, T3001 was tacitly licensed by China's National Drug Administration (NMPA) to conduct Phase 1 clinical trials, and in September of the same year it was approved by OGTR Australia as the first approved lysate virus product in Australia.
may this year, T3001 was approved by the FDA for Phase 1 clinical trials.
, the fastest-growing clinical trial in China is being conducted in a second group of subjects.
In addition to single-drug studies, T3011 conducts preclinical studies in combination with a variety of anti-tumor therapies, including anti-PD-L1, Anti-VEGF (Avastin), apoptosis inhibitor inhibitors (LCL-161), radiotherapy, etc.
Note: The original text has been deleted References . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . Retrieved Aug 6,2020, from Shanghai Pharmaceutical Officer Micro.